share_log

Lexaria Awards Contract To A CRO To Perform The Co's Human Pilot Study #3, Which Will Evaluate A Dual Action GLP-1 + GIP

Lexaria Awards Contract To A CRO To Perform The Co's Human Pilot Study #3, Which Will Evaluate A Dual Action GLP-1 + GIP

Lexaria 將 CRO 授予合同以進行該公司的人體試點研究 #3,該研究將評估雙重作用 GLP-1 + GIP
Benzinga ·  05/23 22:56

First-ever DehydraTECH-processed tirzepatide from Zepbound to be tested in a swallowed oral format

Zepbound 有史以來第一款經脫水處理的曲塞帕肽將以吞服口服形式進行測試

KELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's human pilot study #3, (the "Study") which will evaluate a dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulintropic peptide).

不列顛哥倫比亞省基洛納/ACCESSWIRE/2024年5月23日/藥物遞送平台領域的全球創新者Lexaria Bioscience Corp.(納斯達克股票代碼:LEXXW)(“公司” 或 “Lexaria”)宣佈已聘請合同研究機構(“CRO”)進行該公司的人體試點研究 #3(“研究”),該研究將評估雙作用 GLP-1(胰高血糖素)類肽)+ GIP(葡萄糖依賴性促胰島素肽)。

The Study will be a randomized, crossover investigation that will compare injected tirzepatide (Zepbound by Eli Lilly) to a compound formulated, DehydraTECH-processed tirzepatide derived from Zepbound and rendered into a capsule to be swallowed. There are two study arms:

該研究將是一項隨機交叉研究,將注射的替塞帕肽(由禮來公司製作 Zepbound)與一種配方、脫水處理、源自 Zepbound 並製成膠囊供吞嚥的化合物進行比較。有兩個學習手臂:

  • DehydraTECH-tirzepatide swallowed capsules; and,
  • Injected Zepbound tirzepatide by Eli Lilly.
  • Dehydratech-tirzepatide 吞服膠囊;以及,
  • 由禮來公司注射的 Zepbound tirzepatide。

Tirzepatide is currently available only in its injected form, Zepbound, by Eli Lilly - it is not available in an FDA-approved oral dosage format. The Study will evaluate whether DehydraTECH-processed tirzepatide, when taken orally, offers any absorption into the human bloodstream and, if so, how much. Human tolerability, pharmacokinetics and blood sugar levels will all be recorded and evaluated in this Study.

Tirzepatide目前僅以禮來公司的注射劑形式提供Zepbound——它不以美國食品藥品管理局批准的口服劑量形式提供。該研究將評估Dehydratech加工的替塞帕肽在口服時是否能被人體血液吸收,如果是,吸收量。本研究將記錄和評估人體耐受性、藥代動力學和血糖水平。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論